News

Natural Alternatives International Unveils 2025 Q4 Financials

Natural Alternatives International Unveils 2025 Q4 Financials

Natural Alternatives International's Fiscal Year Overview

Natural Alternatives International, Inc. ('NAI') (Nasdaq: NAII) has reported its financial performance for the fourth quarter and the entire fiscal year. The company marked a net loss of $7.2 million or ($1.20) per diluted share, alongside net sales of $33.9 million during the fourth quarter of the fiscal year. In comparison, the company faced a net loss of $1.9 million or ($0.32) per diluted share in the same quarter of the previous fiscal year.

Sales Performance Analysis

The quarterly net sales showcased an impressive increase of 15%, rising by $4.4 million from $29.5 million in the corresponding period last year to $33.9 million this year. This surge is primarily fueled by a 15% hike in private-label contract manufacturing sales, now totaling $31.8 million. The increase stems from heightened orders from existing clientele and fresh orders from new customers, though it was slightly tempered by a reduction in orders from one major client.

Growth in CarnoSyn® Beta-Alanine Sales

In the same period, revenue from CarnoSyn® beta-alanine, which encompasses royalty, licensing, and raw material sales, rose by 14% to $2.1 million compared to $1.8 million from the last year's fourth quarter. The uptick is attributed to higher raw material sales to existing customers along with an increase in royalty income from this innovative product.

Fiscal Year 2025: Overall Performance

The total net loss recorded for the entirety of fiscal 2025 stands at $13.6 million or ($2.28) per diluted share, a substantial rise from the net loss of $7.2 million or ($1.23) per diluted share documented for fiscal 2024. Just like in the quarterly performance, the fiscal year results were influenced by non-recurring charges associated with litigation settlements and a valuation allowance against deferred tax assets. Excluding said charges, the adjusted net loss for 2025 would reflect at around $7.4 million.

Improved Sales Figures for Fiscal Year

Throughout the fiscal year, net sales surged to $129.9 million, a 14% rise or $16.1 million more than the $113.8 million recorded in the prior year. Private-label contract manufacturing sales accelerated by 16% to $121.8 million compared to $105.4 million previously. However, revenue from CarnoSyn® products dipped slightly by 4% to $8.1 million from $8.4 million.

Future Outlook

The company acknowledged that despite achieving sales growth in the last quarter and across the entire fiscal year, operational losses were driven by inefficient utilization of factory capacities, the financial impact of tax asset valuations, and litigation matters. Moving into fiscal 2026, NAI anticipates a significant increase in sales, aiming for profit in the second half of the year after an expected net loss in the first.

Balance Sheet Highlights

As of the year-end, NAI reported a cash balance of $12.3 million and working capital of $30.5 million compared to $12.0 million and $38.1 million from the previous year, respectively. They also held a borrowing capacity of $9.9 million against a credit facility, with ongoing borrowings totalling $1.9 million.

Insights from Leadership

Mark A. Le Doux, Chairman and CEO of NAI, expressed discontent with the final quarter's results, attributing the negative outcome to the financial implications of the litigation settlement and deferred tax asset adjustments. However, he highlighted a positive trend in revenue and noted a preliminary optimistic outlook for the forthcoming year, saying, "Our focus remains on expanding our client base, diversifying channels, and improving processes to boost our revenue streams and profitability. We sincerely hope to achieve profitability for fiscal 2026. We are committed to maximizing the benefits that our unique TriBsyn™ formulation offers to improve health outcomes, especially for aging demographics by addressing critical health issues like sarcopenia and cardiovascular function.”

Frequently Asked Questions

What is Natural Alternatives International, Inc. known for?

Natural Alternatives International, Inc. is a prominent formulator, manufacturer, and marketer of customized nutritional supplements.

How did NAI perform in Q4 of fiscal year 2025?

The company reported a net loss of $7.2 million with net sales reaching $33.9 million, a 15% increase from the prior year.

What are CarnoSyn® products?

CarnoSyn® is a highly bioavailable beta-alanine supplement that NAI manufactures, used primarily in sports nutrition.

What factors contributed to NAI's net loss?

The net loss was influenced by non-recurring charges, underutilization of the factory, and the financial implications of a litigation settlement.

What are the expectations for fiscal year 2026?

NAI anticipates a net loss in the first half, followed by profitability in the second half of fiscal year 2026.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 0

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontline Healthcare Partners Secures Integracare Inc. Deal

Updated Category News Views 161

Frontline Healthcare Partners Expands Through Strategic Acquisition Frontline Healthcare Partners has recently made headlines with its strategic acquisition of Integracare Inc.. This move indicates a significant step forward in enhancing its portfolio within the private home healthcare space. With Integracare’s reputation for quality care in Toronto and Mississauga,...

Continue Reading
WiMi Innovates with Advanced FPGA-Based Quantum Computing Tech

Updated Category News Views 147

WiMi Hologram Cloud Inc. Develops Cutting-Edge Quantum Computing Technology WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a global leader in Hologram Augmented Reality (AR) technology, has achieved a remarkable milestone by developing a digital quantum computer verification technology based on Field-Programmable Gate Array (FPGA). This advancement signifies a transformative...

Continue Reading
KSP Achieves Excellence in Specialty Pharmacy Recognition Again

Updated Category News Views 244

KSP Recognized as a Specialty Pharmacy Leader KSP, part of McLaren's Specialty Pharmacy, has once again been honored for its outstanding achievements in performance measurement. The Utilization Review Accreditation Commission (URAC) has recognized KSP as a 2024 Specialty Pharmacy Pioneer in its Leaders in Performance Measurement (LPM) program. This accolade underlines...

Continue Reading
Why IREN Limited Shares Are Under Pressure Today in Market

Updated Category News Views 237

Understanding the Recent Drop in IREN Limited Stock IREN Limited (NASDAQ: IREN) has experienced a noticeable decline in share price today as investors react to the company's recent announcements. This comes as a surprise to some, as IREN has shown potential for growth in the past year. Recent Announcements from IREN Limited In a recent update, IREN Limited unveiled plans...

Continue Reading
Deutsche Bank Adjusts S&P 500 Forecast to 5,750 Points

Updated Category News Views 57

Deutsche Bank Updates S&P 500 Year-End Forecast Deutsche Bank has adjusted its year-end target for the S&P 500 index, now forecasting it to reach 5,750 points, up from the previous estimate of 5,500. This significant change stems from strong corporate earnings, an increase in stock buybacks, and a solid demand for equities among investors. Positive Earnings Growth Ahead...

Continue Reading